查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1829860

2025年全球临床肿瘤学下一代定序市场报告

Clinical Oncology Next Generation Sequencing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，临床肿瘤学新一代定序市场快速扩张，市场规模从2024年的5.1亿美元成长至2025年的5.8亿美元，复合年增长率达13.9%。预测期内的成长得益于基因组学研究、癌症生物标记发现、技术进步以及监管核准的推进。

预计未来几年，临床肿瘤学新一代定序市场将快速成长，到2029年将达到9.4亿美元，复合年增长率为12.7%。预测期内的成长归因于癌症发生率的上升、精准医疗、免疫肿瘤学和液态切片。预测期内的主要趋势包括综合基因组分析 (CGP)、免疫肿瘤学、肿瘤进化和异质性、人工智慧和机器学习。

次世代定序(NGS) 是一种用于确定 DNA 片段内核苷酸序列的技术，常用于肿瘤学研究。 NGS 在识别罕见癌症突变、检测遗传性癌症突变携带者以及为标靶治疗提供分子基础方面发挥关键作用。

临床肿瘤学NGS的主要技术包括离子半导体定序、焦磷酸测序、边合成边定序、即时定序、连接定序、可逆染料终止定序和奈米孔定序。离子半导体定序是一种基于检测DNA聚合过程中释放的氢离子的定序技术。临床肿瘤学NGS可应用于筛检、伴随诊断和其他诊断用途等各个领域，并被各种终端用户使用，包括医院实验室、临床研究机构和诊断实验室。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要重新认证医疗设备，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准产品的国内生产以及加快研发更具成本效益的材料来降低风险。

本研究报告是商业研究公司（The Business 次世代定序仪 Company）新研究报告系列的一部分，该系列提供临床肿瘤学次世代定序仪市场统计数据，包括全球市场规模、各地区份额、临床肿瘤学次世代定序仪次世代定序仪市场中的竞争对手、临床肿瘤学下一代次世代定序仪。本临床肿瘤学次世代定序市场研究报告对该行业的现状和未来趋势进行了详细分析，为您提供所需的完整观点。

未来五年12.7%的预测成长率比我们先前对该市场的预测略有下降0.2个百分点。下降的主要原因是美国与其他国家之间关税的影响。美国可能会直接感受到这种影响，因为聚合酵素链锁反应酶和半导体测序晶片的供应链中断，这些晶片来自英国和英国等关键地区，这可能导致个性化癌症治疗计划的延迟和基因组检测成本的增加。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，这种影响可能会更加广泛。

全球癌症患者数量的不断增长预计将在短期内成为临床肿瘤学次世代定序仪市场的成长要素。根据美国癌症协会的数据，光是在美国，2021年就通报了190万例新发癌症病例和60万例癌症相关死亡病例。全球最常见的癌症类型是肺癌、摄护腺癌、大肠癌和乳癌，占所有新发癌症病例的43%。因此，全球癌症发生率的上升预计将推动需求并促进临床肿瘤学下一代定序市场的成长。

癌症发生率的上升预计将推动临床肿瘤学次世代定序仪(NGS) 市场的成长。癌症是指一组以体内异常细胞不受控制地生长扩散为特征的疾病。 NGS 在检测癌症的新型和罕见突变方面发挥关键作用，有助于更好地了解个别肿瘤的分子基础。例如，2024 年 5 月，美国政府机构国家癌症研究所报告称，美国癌症倖存者人数约 1,810 万人。预计到 2032 年这一数字将增加到 2,250 万。到 2040 年，每年新增癌症病例数估计将达到 2,990 万，癌症相关死亡人数估计为 1,530 万人。因此，癌症发生率的上升是推动临床肿瘤学下一代定序市场扩张的主要因素。

临床肿瘤学新一代定序市场中的公司正加大对工作流程自动化的投资，以提高准确性并减少样本间的差异。例如，安捷伦自动化解决方案公司开发了自动化系统，可实现更多并行反应，缩短样本处理时间，提高样本通量，并最大限度地降低样本间的差异。此外，像Sophia Genetics这样的公司正专注于数据驱动型医疗和DNA定序自动化，以增强诊断和治疗能力。

临床肿瘤学次世代定序仪市场的主要企业正在推出像 BenchMark ULTRA PLUS 系统这样的创新产品，以增强其市场竞争力。 BenchMark ULTRA PLUS 系统对于临床实验室，尤其是从事癌症诊断和研究的实验室来说是一个宝贵的工具，因为它确保了诊断测试的准确性和效率，并最终有助于改善患者照护。例如，2022 年 6 月，瑞士製药公司罗氏宣布推出 BenchMark ULTRA PLUS 系统，这是一个用于组织染色的尖端平台。该系统可为临床医生提供快速且准确的检测结果，帮助他们及时为患者做出治疗决策。

2023年1月，美国科学仪器製造商安捷伦科技收购了Avida Biomed，收购金额未揭露。此次收购旨在增强安捷伦科技的次世代定序仪应用，尤其是其用于癌症研究的高性能标靶富集工作流程。透过整合Avida的创新技术，安捷伦旨在强化其精准医疗方法，并将其SureSelect产品组合拓展到临床研究和诊断市场。 Avida Biomed是一家总部位于美国的生物技术公司，专注于临床肿瘤学的次世代定序仪。

临床肿瘤学次世代定序市场的主要企业包括赛默飞世尔科技、Oxford Nanopore Technologies、QIAGEN NV、Myriad Genetics、Illumina, Inc.、F. Hoffmann-La Roche、PerkinElmer、安捷伦科技、Pacific Biosciences of California、Caris Life Sciences、Paradi​​yia Diagnostics Inc、Biomatters Ltd、Partek Inc、Foundation Medicine Inc、Becton Dickinson and Company (BD)、Takara Bio Inc、Creative Biolabs、Mogene LC、Knome Inc、Genomaoma Software GmbH、CLC bio、GnuBIO Inc、Bio-Rad Laborator Inc、Genita、Genomics Inc. Laboratories Inc.、Sysmex Corporation、Veracyte Inc.、Zymo Research Corporation、ArcherDX Inc.、Cepheid、 Karius Inc.、OncoDNA SA、Personal Genome Diagnostics Inc.、PierianDx Inc.

2024年，临床肿瘤学次世代定序仪市场最大的地区是北美。亚太地区是临床肿瘤学次世代定序仪市场的第二大地区。临床肿瘤学次世代定序市场报告涵盖的地区包括亚太地区、西欧、东欧、北美、南美以及中东和非洲。

临床肿瘤学下一代定序市场报告涵盖的国家有澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、义大利、西班牙、加拿大

临床肿瘤学新一代定序市场涵盖具有先进功能和技术的基因定序设备的销售，例如离子半导体定序、焦磷酸测序、边合成边定序 (SBS)、即时定序 (SMRT)、连接定序以及其他用于肿瘤学研究以确定临床肿瘤学所需的碱基序列的技术。市场价值包括服务提供者销售或包含在服务产品中的相关商品的价值。仅包括营业单位之间交易或出售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球临床肿瘤学次世代定序：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球临床肿瘤学下一代定序市场：成长率分析
  • 全球临床肿瘤学下一代定序市场表现：规模与成长，2019-2024
  • 全球临床肿瘤学下一代定序市场预测：规模与成长，2024-2029，2034
  • 全球临床肿瘤学次世代定序：总目标市场（TAM）

第六章 市场细分

  • 全球临床肿瘤学下一代定序市场（按技术、性能和预测），2019-2024 年、2024-2029 年和 2034 年
  • 离子半导体序列
  • 焦磷酸测序
  • 合成序列
  • 即时序列
  • 连接定序
  • 可逆染料终止序列
  • 奈米孔定序
  • 全球临床肿瘤学次世代定序市场的应用、效能与预测，2019-2024 年、2024-2029 年、2034 年
  • 筛检
  • 伴随诊断
  • 其他诊断
  • 全球临床肿瘤学下一代定序市场（按最终用户、性能和预测），2019-2024 年、2024-2029 年和 2034 年
  • 医院检查室
  • 临床研究所
  • 诊断实验室
  • 全球临床肿瘤学次世代定序市场：依离子半导体定序细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 离子质子系统
  • AEON PGM系统
  • ION S5 系统
  • 其他离子半导体定序技术
  • 全球临床肿瘤学次世代定序市场：焦焦磷酸测序定序细分（按类型）、绩效与预测，2019-2024、2024-2029、2034
  • 454焦磷酸测序
  • 其他焦磷酸测序技术
  • 全球临床肿瘤学次世代定序市场：依合成定序细分（按类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • Illumina定序技术
  • SOLiD定序技术
  • 其他合成定序技术
  • 全球临床肿瘤学次世代定序市场：依即时定序类型、表现与预测细分，2019-2024 年、2024-2029 年、2034 年
  • PacBio RS II 系统
  • 续集系统
  • 其他即时定序技术
  • 全球临床肿瘤学次世代定序市场：依连结定序类型细分、效能与预测，2019-2024 年、2024-2029 年、2034 年
  • 螺旋单分子定序
  • 其他连接定序技术
  • 全球临床肿瘤学下一代定序市场：按可逆染料终止定序类型细分、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • Illumina HiSeq
  • Illumina NextSeek
  • 其他可逆染料终止定序技术
  • 全球临床肿瘤学下一代定序市场：按奈米孔定序类型、性能和预测细分，2019-2024 年、2024-2029 年、2034 年
  • 牛津奈米孔技术（MinION、GridION、PromethION）
  • 其他奈米孔定序技术

第七章 区域和国家分析

  • 全球临床肿瘤学下一代定序市场：2019-2024 年、2024-2029 年和 2034 年的区域表现和预测
  • 全球临床肿瘤学次世代定序市场：国家、绩效与预测（2019-2024、2024-2029、2034）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 临床肿瘤学下一代定序市场：竞争格局
  • 临床肿瘤学次世代定序市场：公司简介
    • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
    • Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • F. Hoffmann-La Roche Ltd.
  • PerkinElmer Inc.
  • Agilent Technologies Inc.
  • Pacific Biosciences of California Inc.
  • Caris Life Sciences
  • Paradigm Diagnostics
  • GATC Biotech AG
  • Macrogen Inc.
  • DNASTAR Inc.
  • Exosome Diagnostics Inc.
  • Biomatters Ltd.
  • Partek Inc.
  • Foundation Medicine Inc.
  • Becton Dickinson and Company（BD）
  • Takara Bio Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年临床肿瘤学下一代定序市场：提供新机会的国家
  • 2029年临床肿瘤学次世代定序市场：细分市场带来新机会
  • 临床肿瘤学下一代定序市场 2029：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r32453u

Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.

The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.51 billion in 2024 to $0.58 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

The forecast of 12.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for polymerase chain reaction enzymes and semiconductor-based sequencing chips, sourced from key regions such as Singapore and the UK, which could lead to delayed personalized cancer treatment plans and increased genomic testing costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of cancer cases worldwide is expected to be a contributing factor to the growth of the clinical oncology next-generation sequencing market in the foreseeable future. In 2021, the USA alone reported 1.9 million new cancer cases and 0.6 million cancer-related deaths, according to data from the American Cancer Society. The most common cancer types globally include lung, prostate, colorectal, and breast cancer, accounting for 43% of all new cancer cases. Consequently, the rising global incidence of cancer is likely to drive demand and foster growth in the clinical oncology next-generation sequencing market.

The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.

Companies in the clinical oncology next-generation sequencing market are increasingly investing in workflow automation to enhance precision and reduce sample-to-sample variability. For example, Agilent automation solutions have developed an automated system that enables a higher number of parallel reactions, reduces sample processing time, increases the volume of processed samples, and minimizes variability between samples. Additionally, companies like Sophia Genetics are focusing on data-driven medicine and the automation of DNA sequencing to enhance diagnostic and treatment capabilities.

Major companies operating in the clinical oncology next-generation sequencing market are introducing innovative products like the BenchMark ULTRA PLUS system to enhance their market competitiveness. The BenchMark ULTRA PLUS System is a valuable tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, ultimately contributing to improved patient care. For example, in June 2022, the Switzerland-based pharmaceutical company Roche unveiled the BenchMark ULTRA PLUS system, their state-of-the-art platform for tissue staining. This system provides clinicians with rapid and accurate test results, aiding in timely treatment decisions for patients.

In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Clinical Oncology Next Generation Sequencing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for clinical oncology next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical oncology next generation sequencing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing
  • 2) By Application: Screening; Companion Diagnostics; Other Diagnostics
  • 3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
  • Subsegments:
  • 1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies
  • 2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
  • 3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
  • 4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
  • 5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
  • 6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
  • 7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
  • Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Agilent Technologies Inc.; Pacific Biosciences of California Inc.; Caris Life Sciences; Paradigm Diagnostics; GATC Biotech AG; Macrogen Inc.; DNASTAR Inc.; Exosome Diagnostics Inc.; Biomatters Ltd.; Partek Inc.; Foundation Medicine Inc.; Becton Dickinson and Company (BD); Takara Bio Inc.; Creative Biolabs; Mogene LC; Knome Inc.; Genomatix Software GmbH; CLC bio; GnuBIO Inc.; Bio-Rad Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation; ArcherDX Inc.; Cepheid; Karius Inc.; OncoDNA S.A.; Personal Genome Diagnostics Inc.; PierianDx Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Clinical Oncology Next Generation Sequencing Market Characteristics

3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies

4. Clinical Oncology Next Generation Sequencing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Clinical Oncology Next Generation Sequencing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Clinical Oncology Next Generation Sequencing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Clinical Oncology Next Generation Sequencing Market Growth Rate Analysis
  • 5.4. Global Clinical Oncology Next Generation Sequencing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Clinical Oncology Next Generation Sequencing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM)

6. Clinical Oncology Next Generation Sequencing Market Segmentation

  • 6.1. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing
  • Real Time Sequencing
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing
  • 6.2. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Screening
  • Companion Diagnostics
  • Other Diagnostics
  • 6.3. Global Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Laboratories
  • Clinical Research Organizations
  • Diagnostic Laboratories
  • 6.4. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ion Semiconductor Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ion Proton System
  • Ion PGM System
  • Ion S5 System
  • Other Ion Semiconductor Sequencing Technologies
  • 6.5. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Pyro-Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 454 Pyrosequencing
  • Other Pyro-Sequencing Technologies
  • 6.6. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Synthesis Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Illumina Sequencing Technology
  • SOLiD Sequencing Technology
  • Other Synthesis Sequencing Technologies
  • 6.7. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Real-Time Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PacBio RS II System
  • Sequel System
  • Other Real-Time Sequencing Technologies
  • 6.8. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Ligation Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Helicos Single Molecule Sequencing
  • Other Ligation Sequencing Technologies
  • 6.9. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Reversible Dye Termination Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Illumina HiSeq
  • Illumina NextSeq
  • Other Reversible Dye Termination Sequencing Technologies
  • 6.10. Global Clinical Oncology Next Generation Sequencing Market, Sub-Segmentation Of Nano-Pore Sequencing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oxford Nanopore Technologies (MinION, GridION, PromethION)
  • Other Nano-Pore Sequencing Technologies

7. Clinical Oncology Next Generation Sequencing Market Regional And Country Analysis

  • 7.1. Global Clinical Oncology Next Generation Sequencing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Clinical Oncology Next Generation Sequencing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Clinical Oncology Next Generation Sequencing Market

  • 8.1. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Clinical Oncology Next Generation Sequencing Market

  • 9.1. China Clinical Oncology Next Generation Sequencing Market Overview
  • 9.2. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Clinical Oncology Next Generation Sequencing Market

  • 10.1. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Clinical Oncology Next Generation Sequencing Market

  • 11.1. Japan Clinical Oncology Next Generation Sequencing Market Overview
  • 11.2. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Clinical Oncology Next Generation Sequencing Market

  • 12.1. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Clinical Oncology Next Generation Sequencing Market

  • 13.1. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Clinical Oncology Next Generation Sequencing Market

  • 14.1. South Korea Clinical Oncology Next Generation Sequencing Market Overview
  • 14.2. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Clinical Oncology Next Generation Sequencing Market

  • 15.1. Western Europe Clinical Oncology Next Generation Sequencing Market Overview
  • 15.2. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Clinical Oncology Next Generation Sequencing Market

  • 16.1. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Clinical Oncology Next Generation Sequencing Market

  • 17.1. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Clinical Oncology Next Generation Sequencing Market

  • 18.1. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Clinical Oncology Next Generation Sequencing Market

  • 19.1. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Clinical Oncology Next Generation Sequencing Market

  • 20.1. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Clinical Oncology Next Generation Sequencing Market

  • 21.1. Eastern Europe Clinical Oncology Next Generation Sequencing Market Overview
  • 21.2. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Clinical Oncology Next Generation Sequencing Market

  • 22.1. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Clinical Oncology Next Generation Sequencing Market

  • 23.1. North America Clinical Oncology Next Generation Sequencing Market Overview
  • 23.2. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Clinical Oncology Next Generation Sequencing Market

  • 24.1. USA Clinical Oncology Next Generation Sequencing Market Overview
  • 24.2. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Clinical Oncology Next Generation Sequencing Market

  • 25.1. Canada Clinical Oncology Next Generation Sequencing Market Overview
  • 25.2. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Clinical Oncology Next Generation Sequencing Market

  • 26.1. South America Clinical Oncology Next Generation Sequencing Market Overview
  • 26.2. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Clinical Oncology Next Generation Sequencing Market

  • 27.1. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Clinical Oncology Next Generation Sequencing Market

  • 28.1. Middle East Clinical Oncology Next Generation Sequencing Market Overview
  • 28.2. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Clinical Oncology Next Generation Sequencing Market

  • 29.1. Africa Clinical Oncology Next Generation Sequencing Market Overview
  • 29.2. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Clinical Oncology Next Generation Sequencing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Clinical Oncology Next Generation Sequencing Market Competitive Landscape And Company Profiles

  • 30.1. Clinical Oncology Next Generation Sequencing Market Competitive Landscape
  • 30.2. Clinical Oncology Next Generation Sequencing Market Company Profiles
    • 30.2.1. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Oxford Nanopore Technologies Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Myriad Genetics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Clinical Oncology Next Generation Sequencing Market Other Major And Innovative Companies

  • 31.1. F. Hoffmann-La Roche Ltd.
  • 31.2. PerkinElmer Inc.
  • 31.3. Agilent Technologies Inc.
  • 31.4. Pacific Biosciences of California Inc.
  • 31.5. Caris Life Sciences
  • 31.6. Paradigm Diagnostics
  • 31.7. GATC Biotech AG
  • 31.8. Macrogen Inc.
  • 31.9. DNASTAR Inc.
  • 31.10. Exosome Diagnostics Inc.
  • 31.11. Biomatters Ltd.
  • 31.12. Partek Inc.
  • 31.13. Foundation Medicine Inc.
  • 31.14. Becton Dickinson and Company (BD)
  • 31.15. Takara Bio Inc.

32. Global Clinical Oncology Next Generation Sequencing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Clinical Oncology Next Generation Sequencing Market

34. Recent Developments In The Clinical Oncology Next Generation Sequencing Market

35. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies

  • 35.1 Clinical Oncology Next Generation Sequencing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Clinical Oncology Next Generation Sequencing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Clinical Oncology Next Generation Sequencing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer